Key Segments:
By Product
-
Ozempic
-
Trulicity
-
Mounjaro
-
Wegovy
-
Rybelsus
-
Saxenda
-
Victoza
-
Zepbound
-
Other Products
By Application
-
Type 2 Diabetes Mellitus
-
Obesity
-
Others
By Route of Administration
-
Parenteral
-
Oral
By Distribution Channel
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
-
Others
Regional Coverage:
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
Rest of Asia Pacific
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players in the Asia Pacific GLP-1 Receptor Agonist Market include Novo Nordisk A/S, Eli Lilly and Company, Innovent Biologics, Inc., Hengrui Pharmaceutical Co., Ltd., and Dr. Reddy’s Laboratories Ltd., among others.
Key opportunities include expanding generic manufacturing in India, rising obesity-indication approvals, and growing domestic pipeline development in China.
The market is driven by rapid generic entry following patent expiry, expanding domestic manufacturing, and growing diabetes and obesity treatment access across the region.
The Ozempic segment dominated the Asia Pacific GLP-1 Receptor Agonist Market, accounting for approximately 29.80% share in 2025.
China dominated the Asia Pacific GLP-1 Receptor Agonist Market in 2025 with a 38.00% share, supported by its large diabetic population and rapid domestic manufacturing growth.
